journal article·2011-04

Drug permeation across intestinal epithelial cells using porous silicon nanoparticles

Luis M. Bimbo, Ermei Mäkilä, Timo Laaksonen, Vesa-Pekka Lehto, Jarno Salonen, Jouni Hirvonen, Hélder A. Santos

Biomaterials· Volume 32· Issue 10
Publisher page

Abstract

Mesoporous silicon particles hold great potential in improving the solubility of otherwise poorly soluble drugs. To effectively translate this feature into the clinic, especially via oral or parenteral administration, a thorough understanding of the interactions of the micro- and nanosized material with the physiological environment during the delivery process is required. In the present study, the behaviour of thermally oxidized porous silicon particles of different sizes interacting with Caco-2 cells (both non-differentiated and polarized monolayers) was investigated in order to establish their fate in a model of intestinal epithelial cell barrier. Particle interactions and TNF-α were measured in RAW 264.7 macrophages, while cell viabilities, reactive oxygen species and nitric oxide levels, together with transmission electron microscope images of the polarized monolayers, were assessed with both the Caco-2 cells and RAW 264.7 macrophages. The results showed a concentration and size dependent influence on cell viability and ROS-, NO- and TNF-α levels. There was no evidence of the porous nanoparticles crossing the Caco-2 cell monolayers, yet increased permeation of the loaded poorly soluble drug, griseofulvin, was shown.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Silicon Nanostructures and Photoluminescence · Nanoparticle-Based Drug Delivery · Graphene and Nanomaterials Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (48)

Show source-provided references
1. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs10.1016/j.drudis.2007.09.005 ↗
2. Nanosizing–oral formulation development and biopharmaceutical evaluation10.1016/j.addr.2007.05.003 ↗
3. Controlled release technologies for drug delivery10.1016/S1359-6446(03)02874-5 ↗
4. Novel platforms for oral drug delivery10.1007/s11095-008-9803-0 ↗
5. Porous silicon in drug delivery devices and materials10.1016/j.addr.2008.03.017 ↗
6. Mesoporous silicon in drug delivery applications10.1002/jps.20999 ↗
7. Mesoporous silicon: a platform for the delivery of therapeutics10.1517/17425247.4.2.101 ↗
8. The biocompatibility of porous silicon in tissues of the eye10.1016/j.biomaterials.2009.02.008 ↗
9. Bioactive silicon structure fabrication through nanoetching techniques10.1002/adma.19950071215 ↗
10. Mesoporous silicon microparticles for oral drug delivery: loading and release of five model drugs10.1016/j.jconrel.2005.08.017 ↗
11. Oxidized mesoporous silicon microparticles for improved oral delivery of poorly soluble drugs10.1021/mp900221e ↗
12. Microfabricated porous silicon particles enhance paracellular delivery of insulin across intestinal Caco-2 cell monolayers10.1023/A:1022211127890 ↗
13. In vivo delivery of a peptide, ghrelin antagonist, with mesoporous silicon microparticles10.1016/j.jconrel.2009.03.017 ↗
14. Evaluation of mesoporous TCPSi, MCM-41, SBA-15, and TUD-1 materials as API carriers for oral drug delivery10.1080/10717540601098823 ↗
15. Sustained small interfering RNA delivery by mesoporous silicon particles10.1158/0008-5472.CAN-09-3931 ↗
16. Biocompatibility of thermally hydrocarbonized porous silicon nanoparticles and their biodistribution in rats10.1021/nn901657w ↗
17. Comparison of cytotoxic and inflammatory responses of photoluminescent silicon nanoparticles with silicon micron-sized particles in RAW 264.7 macrophages10.1002/jat.1382 ↗
18. Biodegradable luminescent porous silicon nanoparticles for in vivo applications10.1038/nmat2398 ↗
19. Thermal oxidation of free-standing porous silicon films10.1063/1.118294 ↗
20. In vitro cytotoxicity of porous silicon microparticles: effect of the particle concentration, surface chemistry and size10.1016/j.actbio.2009.12.043 ↗
21. Cytotoxicity study of ordered mesoporous silica MCM-41 and SBA-15 microparticles on Caco-2 cells10.1016/j.ejpb.2009.12.006 ↗
22. Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs10.1023/A:1011910801212 ↗
23. Mesoporous materials for drug delivery10.1002/anie.200604488 ↗
24. Cytotoxicity suppression and cellular uptake enhancement of surface modified magnetic nanoparticles10.1016/j.biomaterials.2004.05.022 ↗
25. Toxic potential of materials at the nanolevel10.1126/science.1114397 ↗
26. Phenotypic non-equivalence of murine (monocyte-) macrophage cells in biomaterial and inflammatory models10.1002/jbm.a.31930 ↗
27. In vitro assessments of nanomaterial toxicity10.1016/j.addr.2009.03.005 ↗
28. Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals10.1038/nm1577 ↗
29. Generation of reactive oxygen species from porous silicon microparticles in cell culture medium10.1002/jbm.a.32610 ↗
30. Nitric oxide production in Caco-2 cells exposed to different inducers, inhibitors and natural toxins10.1016/S0887-2333(01)00023-6 ↗
31. Nitric oxide dilates tight junctions and depletes ATP in cultured Caco-2BBe intestinal epithelial monolayers
32. Oxidative stress and pro-inflammatory responses induced by silica nanoparticles in vivo and in vitro10.1016/j.toxlet.2008.10.012 ↗
33. Exposure of the murine RAW 264.7 macrophage cell line to hydroxyapatite dispersions of various composition and morphology: assessment of cytotoxicity, activation and stress response10.1016/j.tiv.2009.01.007 ↗
34. Differential binding of cytokines to environmentally relevant particles: a possible source for misinterpretation of in vitro results?10.1016/j.toxlet.2007.10.014 ↗
35. Failure of MTT as a toxicity testing agent for mesoporous silicon microparticles10.1021/tx700326b ↗
36. Limitations and relative utility of screening assays to assess engineered nanoparticle toxicity in a human cell line10.1016/j.taap.2008.09.030 ↗
37. Cytotoxicity and genotoxicity of silver nanoparticles in human cells10.1021/nn800596w ↗
38. A homogeneous assay to measure live and dead cells in the same sample by detecting different protease markers10.1016/j.ab.2007.04.007 ↗
39. Nanoparticle-mediated cellular response is size-dependent10.1038/nnano.2008.30 ↗
40. Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells10.1021/nl052396o ↗
41. The effect of particle design on cellular internalization pathways10.1073/pnas.0801763105 ↗
42. Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis10.1042/bj20031253 ↗
43. Synergistic induction of tumor necrosis factor alpha by bacterial lipopolysaccharide and lipoteichoic acid in combination with polytetrafluoroethylene particles in a murine macrophage cell line RAW 264.710.1002/(SICI)1097-4636(199606)31:2<251::AID-JBM12>3.0.CO;2-O ↗
44. Drug permeability and mucoadhesion properties of thiolated trimethyl chitosan nanoparticles in oral insulin delivery10.1016/j.biomaterials.2009.06.055 ↗
45. Spherical mesoporous silica nanoparticles for loading and release of the poorly water-soluble drug telmisartan10.1016/j.jconrel.2010.04.029 ↗
46. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells10.1016/0006-291X(91)91647-U ↗
47. Enhanced in vitro permeation of furosemide loaded into thermally carbonized mesoporous silicon (TCPSi) microparticles10.1016/j.ejpb.2006.11.021 ↗
48. Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability?10.1002/jps.21650 ↗